Announced a financing method combining the 22nd series of stock acquisition rights (with an exercise price adjustment clause) and a loan facility of 500 million yen to secure funds for the Phase 3 clinical trial. The 23rd and 24th series of stock acquisition rights initially have fixed exercise prices but may be subject to the adjustment clause depending on conditions. The total expected proceeds are 4,175 million yen, with a total potential dilution ratio of 24.35%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4575","jir_company_name":"CanBas Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4575-20261014-04.pdf","jir_short_summary":"Announced a financing method combining the 22nd series of stock acquisition rights (with an exercise price adjustment clause) and a loan facility of 500 million yen to secure funds for the Phase 3 clinical trial. The 23rd and 24th series of stock acquisition rights initially have fixed exercise prices but may be subject to the adjustment clause depending on conditions. The total expected proceeds are 4,175 million yen, with a total potential dilution ratio of 24.35%.","jir_summary":"### Overview of Capital Policy\nThese materials explain the design of a financing structure that combines stock acquisition rights and lending to meet funding needs for the Phase 3 clinical trial. The 22nd series of stock acquisition rights includes an exercise price adjustment clause to achieve a high degree of funding certainty, and a loan facility is being established in parallel. The 23rd and 24th series of stock acquisition rights initially have fixed exercise prices, but the adjustment clause can be applied by resolution of the Board of Directors. This approach aims to implement initial investments for the clinical trial flexibly while mitigating shareholder dilution.\n\n### Use of Funds and Risk Management\nFunds will be applied to the CBP501 Phase 3 clinical trial in Europe and general business operating expenses. Execution of the loan facility will be carried out according to the progress of the Phase 3 trial; the borrowings will be unsecured, but a reservation agreement will be concluded to create a pledge on time deposits. By accommodating multiple timing needs for funding, the company diversifies the risk of financing failure and establishes a framework to undertake upfront investment expenditures with agility.","jir_financial_highlights":"Expected Proceeds: 4,175 million yen (after deduction of 22 million yen in issuance expenses) (Unknown)\nPotential Dilution Ratio: Total 24.35% (Unknown)","jir_category":"","jir_hashtags":"#CanBas, #CapitalPolicy_StockAcquisitionRights, #ClinicalTrialFundraising","jir_key_figures":"Expected Proceeds: 4,175 million yen\nPotential Dilution Ratio: Total 24.35%\nLoan Facility Amount: 500 million yen","jir_meta_title":"CanBas Co., Ltd. - Details of Financing via Stock Acquisition Rights and Loan Facility | October 2026","jir_meta_description":"Supplementary materials from CanBas Co., Ltd. explain a financing design combining the 22nd\u201324th series of stock acquisition rights and a loan facility to secure funds for the Phase 3 clinical trial. Key points: expected proceeds of 4,175 million yen and potential dilution ratio of 24.35%.","jir_og_title":"CanBas Co., Ltd. - Optimizing Financing with Stock Acquisition Rights and Loan Facility | October 2026","jir_og_description":"Overview of financing combining stock acquisition rights and a loan facility to secure funds for the Phase 3 clinical trial. Key items include expected proceeds of 4,175 million yen and a potential dilution ratio of 24.35%.","jir_og_image_url":"\/assets\/og\/company-capital_policy.jpg","jir_chart_data_collection":"[]","ir_related_company":58229,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-130831","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n